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Objectives: To examine the association between β-blocker prescription and first 
primary-care consultation for knee osteoarthritis (OA), hip OA, knee pain and hip pain. 
Methods: Data source: Clinical Practice Research Datalink. Participants aged ≥40 
years in receipt of new oral β-blocker prescriptions were propensity score (PS) 
matched to an unexposed control. Cox proportional hazard ratios (HRs) and 95% 
confidence intervals (CI) were calculated, and adjusted for non-osteoporotic fractures,  
number of primary-care consultations for knee or hip injury, and, the number of 
primary-care consultations, out-patient referrals and hospitalizations in the 12-months 
preceding cohort entry. Analysis was stratified according to β-blocker class and for 
commonly prescribed drugs. P<0.05 was statistically significant.    
Results: 111,718 β-blocker exposed participants were 1:1 PS matched to unexposed 
controls. β-blocker prescription was associated with reduced cumulative risk of knee 
OA, knee pain, and hip pain consultations with aHR(95%CI) 0.90(0.83–0.98); 
0.88(0.83–0.92), and 0.85(0.79–0.90), respectively. Propranolol and atenolol were 
associated with a lower incidence of knee OA and knee pain consultations with aHRs 
between 0.78-0.91. β-blockers were associated with reduced incidence of consultation 
for large-joint lower-limb OA/pain as a composite outcome, defined as earliest of knee 
OA, knee pain, hip OA or hip pain consultation (aHR(95%CI) 0.87(0.84-0.90)). 
Conclusion: Commonly used β-blockers have analgesic properties for musculoskeletal 
pain. Atenolol might be a therapeutic option for OA and cardiovascular co-morbidities 
in which β-blockers are indicated, while propranolol may be suitable for people with 
co-morbid anxiety. A confirmatory randomised controlled trial is needed before clinical 




















Key messages  
• In this large study, β-blockers reduced consultations for knee OA, and knee or 
hip pain.  
• Atenolol could be considered for people with osteoarthritis and co-morbidities 
for which β-blockers are indicated. 

















Osteoarthritis (OA) is the commonest form of arthritis and affects approximately half 
of all adults aged >50 years (1, 2). The pharmacologic management of OA is centred 
around optimising analgesia, but first-line drugs only have modest efficacy (3). 
Additionally, non-steroidal anti-inflammatory drugs (NSAIDs) may cause 
gastrointestinal, cardiovascular, and renal side-effects, particularly in the age groups 
affected by OA (4). People with OA are already at high risk of these adverse-events 
due to multi-morbidity (5, 6). Consequently, the use of opioids for OA pain has 
increased recently (7). However, opioids are poorly tolerated and may cause serious 
side-effects and dependency, and evidence for their efficacy in OA pain is limited (8, 
9). Thus, there is an unmet need for developing a safe analgesic for OA.  
Small uncontrolled studies suggest that β-adrenoreceptor blocking drugs (β-blockers) 
have anti-nociceptive effects in fibromyalgia, temporo-mandibular dysfunction, and 
migraine (10-12). Additionally, polymorphisms in the β2-adrenoreceptor gene 
associates with chronic painful conditions (13-15). Recently, we reported a negative 
association between β-blocker prescription and severe knee pain and opioid 
prescription in adults with knee or hip OA awaiting total joint replacement (16). 
However, these results were not confirmed in another study (17), and, whether the 
analgesic effect is specific to a sub-class of β-blockers is not known. 
Thus, the purpose of this study was to investigate the analgesic potential of β-blockers 
in a primary-care cohort. The specific objectives were to examine the association 
between β-blocker prescription and first primary-care consultation for knee OA 












to identify the class of β-blockers, and specific drugs, that are most likely to have an 
analgesic effect.  
Methods:  
Study Design: Cohort study 
Data source: The Clinical Practice Research Datalink (CPRD). CPRD is a longitudinal 
anonymised electronic database containing health records of >10 million people in the 
UK (18). CPRD participants are representative of the UK population in terms of age, 
sex, and ethnicity (18). It contains details of diagnoses, symptoms and signs, and 
referral details stored as Read code and, records of primary-care prescriptions stored 
as drug names.  
Ethical approval: ISAC of the MHRA (Reference: 18_227R).  
Study population: CPRD registered participants aged ≥40 years, contributing data in 
general practice surgeries that met the data quality standards of CPRD between 1st 
January 1990 and 31st December 2017. This age cut-off was chosen as both the 
probability of exposure and outcome is low in the under 40s. 
Exposure: First ever continuous β-blocker prescription, defined as ≥2 prescription for 
any oral β-blocker within a 60-day period. In the UK, primary-care prescriptions are 
usually issued every 4 weeks. We selected participants with ≥2 prescriptions within 
60-days to exclude those who experience side-effects and discontinue treatment 
shortly after it was commenced. 
Unexposed: Participants without prescription of β-blockers.  
It is common to choose active comparators in pharmacoepidemiology studies. We did 
not use active comparator controls because there is a hierarchy in the use of drugs for 












instance, NICE recommend β-blockers for resistant hypertension that has failed to 
respond to other anti-hypertensive agents. In contrast, they recommended β-blockers 
first line for atrial fibrillation, angina and heart failure. Thus, an active comparator study 
would introduce greater bias by comparing people with different severity of 
cardiovascular illnesses.  
Propensity Score (PS) matching: As participants prescribed β-blockers are likely to 
have comorbidities and be older, a PS for β-blocker prescription was calculated and 
1:1 matching undertaken to ensure unexposed and exposed participants were 
otherwise comparable. The PS included:  
[1] demographic factors: age, sex, current smoker (yes, no), general practice surgery 
level index of multiple deprivation score. 
[2] comorbidities: overweight or obese (body mass index (BMI) ≥25 kg/m2) 
hypertension, angina, myocardial infarction, heart failure, atrial fibrillation, stroke, 
chronic kidney disease, diabetes, anxiety, migraine, and duration in years of each 
cardiovascular comorbidity prior to cohort entry; and  
[3] prescriptions: calcium channel blockers, ACE inhibitors, angiotensin II receptor 
antagonists, bendroflumethiazide, aldosterone antagonists, loop diuretics, alfa-
adrenoreceptor blocking drugs, aspirin, clopidogrel, statins, fibrates.   
Outcomes: Primary-care consultation for knee OA, hip OA, knee pain, and hip pain 
(Table S2: Codelist). A primary-care diagnosis of OA at either the knee, hip or hands 
has a positive predictive value of 79.8%-82% in validation studies in the CPRD and 
similar primary-care databases (19, 20). 
Index date: Date of the first of two consecutive prescriptions in the exposed (new user 
design). Unexposed participants were assigned the index date of their matched 












Exclusion criteria: Consultation for any of the following prior to the index date: 
• OA at any joint 
• Knee, hip, neck or back pain  
• Autoimmune inflammatory rheumatic diseases, or gout 
• Radiculopathy, or neuropathy 
• Fibromyalgia 
• Contra-indications to β-blockers: asthma, chronic obstructive pulmonary 
disease, peripheral vascular disease, heart block, aortic stenosis, hypertrophic 
obstructive cardiomyopathy 
• Two prescriptions for opioids, NSAIDs, gabapentin, pregabalin, duloxetine or 
amitriptyline in any 60-day period prior to the index date. 
• Additionally, participants with <2 years of registration data before index date 
were excluded to reduce the chance of prevalent conditions (e.g. long-standing 
OA or pain) being considered as incident outcomes. 
It is typical to require one-year disease free registration as entry criteria in studies 
using consultation-based databases. However, people with OA may not consult their 
GP in a given 12-month period. Thus, a disease-free registration of 2-years prior to 
cohort entry was chosen in consultation with the GP-expert in the team to minimises 
the chance of prevalent OA cases being classified as incident outcome(s). 
Follow-up: Exposed and unexposed participants were followed-up from index date  
until the earliest of outcome of interest, death date, transfer out date, date of last data 
collection, study end date (31/12/2017), or date of last prescription of β-blockers plus 
28 days (typical duration of primary-care prescriptions in UK) in the exposed, and an 












matched exposed person. The follow-up period of participants not experiencing an 
outcome was censored. Given the well-known effects of propranolol on pain sensitivity 
(21), we anticipated β-blockers to have an analgesic effect in the short term and follow-
up period >28 days after the date of last β-blocker prescription was disregarded from 
primary analysis a priori. In a secondary analysis, we extended the follow-up period to 
earliest of outcome of interest, death date, transfer out date, date of last data 
collection, and study end date (31/12/2017). 
Statistical Analysis The PS was calculated using a cumulative logit regression model. 
Greedy nearest neighbour 1:1 matching without replacement, specifying a maximum 
calliper width of 0.001 was undertaken. Participants with missing data on smoking and 
BMI were classified as non-smoker and normal BMI respectively. This approach was 
chosen due to >50% missing data on these variables, and because they are missing 
not at random in consultation-based databases such as CPRD (22-25). Mean, 
standard deviation (SD), n (%), and standardised difference (d) were used to examine 
the covariate balance between exposed and unexposed participants. If d was more 
than +0.10 or less than -0.10, the variable was included in the model as a covariate 
as per Nguyen et al (26).  
Cox proportional hazard ratios (HRs) and 95% confidence interval (CI) were calculated 
for each outcome after checking that proportional hazard assumptions were met using 
log-log plots and a formal test to assess departure from proportional hazards (Figure 
S1). Nelson-Aalen graphs were plotted. Covariates likely to influence outcomes but 
are not related to exposure (i.e. number of GP consultations for knee or hip injury, and 
non-osteoporotic fractures prior to the index date) or which reflect general health-
seeking behaviour and may influence consultation for musculoskeletal pain (i.e. 












the 12-month period preceding cohort entry) were included in the model. Non-
osteoporotic fractures were included as a surrogate of knee or hip injury. They were 
defined in this study as fractures between the ages of 19-49 years in women, and 19-
59 years in men respectively. Vertebral, femoral and distal radius fractures were 
excluded as these are target sites for osteoporotic fractures.  
The analyses were stratified according to the class of β-blocker used, namely β1 
selective or non-selective, intrinsic sympathomimetic activity (ISA) present or absent, 
membrane stabilising effect (MSE) present or absent, and high or low lipophilic 
properties; and commonly prescribed β-blocker drugs. Robustness of results were 
assessed using first of OA or pain consultation at the knee or hip as an outcome. 
Sensitivity analysis: Given the extent of missing data on smoking status and BMI, a 
complete-case analysis was performed. In this, exposed and unexposed participants 
with missing data were excluded, 1:1 PS matching was performed and the analysis 
adjusted for the a priori selected covariates listed above. Data management and 
analysis were performed using Stata(v15). Statistical significance was considered at 
p<0.05. 
Results  
Data for 223,436 1:1 PS-matched β-blocker exposed (n=111,718) and unexposed 
(n=111,718) participants were included (Figure S2). The mean (SD) follow-up period 
while receiving β-blocker prescription and total follow-up period, including when not 
prescribed β-blockers was 2.75 (4.03) and 11.29 (6.59) years respectively in the 
exposed. The corresponding follow-up for the unexposed participants was 2.35 (3.17)  
and 10.02 (6.38) years respectively. There was covariate balance after PS-matching 












Age was included in the model to account for the imbalance. After PS matching, 
unexposed and unexposed participants had similar number of primary-care 
consultations in the preceding 12-months, with mean (SD) 5.27 (7.05) and 5.81 (6.92) 
visits, respectively, d = 0.08. 
β-blocker prescription was associated with reduced cumulative risk of incident 
primary-care consultation for knee OA (aHR(95%CI) 0.90(0.83–0.98)), knee pain 
(aHR(95%CI)  0.88(0.83 – 0.92)) and hip pain (aHR(95%CI) 0.85(0.79 – 0.90)) (Table 
1, Figure 1). On secondary analysis, there was no association between β-blocker 
prescription and primary-care consultation for knee OA or hip OA when the follow-up 
period extended beyond the end of β-blocker prescription, while there was an 
increased incidence of primary-care consultation for knee pain or hip pain (Table 2).   
Of the β-blocker classes that could be assessed, high lipophilic non-selective β-
blockers were associated with lower cumulative incidence of primary-care consultation 
for knee OA and knee pain with aHR(95%CI) of 0.78(0.63-0.95) and 0.80(0.72-0.89) 
respectively (Table 3). Similarly, low lipophilic, β1-selective drugs without MSE or ISA 
reduced the cumulative incidence of primary-care consultation for knee pain 
(aHR(95%CI) 0.88(0.80-0.93)) and knee OA (aHR(95%CI) 0.92(0.84-1.01)). 
Additionally, lipophilic β1-selective and low-lipophilic non-selective β-blockers, without 
MSE or ISA, were associated with a reduced cumulative incidence of primary-care 
consultation for knee pain with aHR(95%CI) 0.81(0.66-1.00)), and 0.85(0.71-1.02), 
respectively. There was a trend for similar effects when hip OA and hip pain 
consultations were the outcomes of interest (Table 3; Figure S3). When data were 
stratified according to individual drugs, there was a significant protective effect for 
propranolol and atenolol for knee OA and knee pain consultations and, for atenolol for 












prescription to associate with a lower cumulative risk of hip pain consultation (Table 4; 
Figures S4). 
β-blockers were associated with reduced cumulative risk of primary-care consultation 
for large-joint lower-limb OA and/or pain, defined as the earliest of knee OA, knee 
pain, hip OA or hip pain (aHR(95%CI) 0.87(0.84-0.90)). The aHR (95%CI) was 0.80 
(0.73-0.87) for propranolol, and 0.85 (0.82-0.89) for atenolol. On complete case PS-
matched analysis all covariates were balanced. Exposure to β-blockers was 
associated with lower cumulative incidence of primary-care consultation for knee OA 
(aHR (95%CI) 0.85(0.76-0.96)), knee pain (0.77(0.72-0.82)), hip pain (0.70(0.64-
0.76)) and hip OA(0.85(0.72-1.02)), adjusted for the a priori selected covariates.  
Discussion  
This primary-care based study reports that β-blocker prescription was associated with 
reduced primary-care consultation for knee OA, knee pain, and hip pain. Interestingly, 
the effect disappeared after the end of β-blocker prescription, and participants had 
more consultations for knee and hip pain in this period. This suggests that the effect 
of β-blockers may potentially be due to analgesia rather than structure-modification. 
However, we did not assess the latter in this study.  
The greatest effect size was  observed for propranolol, a non-selective lipophilic β-
blocker with MSE. Analgesic effects of propranolol have been reported. In a 
randomised double-blind placebo-controlled crossover study (n=40), propranolol 
significantly lowered pain scores due to temporomandibular dysfunction (27). Similar 
findings were observed in fibromyalgia and temporomandibular dysfunction in 
controlled studies shortly after low-dose intravenous propranolol (0.1 mg/kg) (10). 












analgesic effect for propranolol was not demonstrated in people with extensive burns 
and in other experimental models of pain (29, 30). Propranolol is used in the treatment 
of anxiety, and 21% of OA patients have comorbid anxiety (31) making it particularly 
attractive in this scenario. 
The β1 adrenoreceptor selective drug atenolol was associated with reduced 
cumulative risk of primary-care consultation for knee OA,  knee pain and hip pain. 
Identical in properties to atenolol, esmolol, also has an analgesic effect (32). It reduces 
both intraoperative (Standard Mean Difference (SMD) (95%CI) -1.60(-2.25 to -0.96)) 
and post-anaesthesia opioid consumption (SMD (95%CI) -1.21(-1.66 to -0.77)) (32). 
Atenolol is used for the treatment of cardiovascular conditions such as angina, 
hypertension and supraventricular tachycardia, and our findings suggest that it might 
be suitable for the treatment of cardiovascular comorbidities in symptomatic OA 
patients. However, confirmation of our findings in a randomised controlled trial (RCT) 
is needed before practice is changed. 
The analgesic effect of β-blockers is mediated by β2 adrenoreceptor blockade. β2 
adrenoreceptors are present on peripheral nociceptors, dorsal root ganglia and 
superficial dorsal horn, and their stimulation results in hyperalgesia that is blocked by 
either non-selective or β2 adrenoreceptor selective drugs (33-35), but not by 
indomethacin (35). The analgesic effect of β-blockers does not seem to be mediated 
by the β1 adrenoreceptor. For example, the hyperalgesic state in low catechol-O-
methyl transferase gene activity is blocked by propranolol but not by selective β1-
adrenoreceptor blockers (36). Non-selective β-blockers reduce the negative affective 
component of pain (37), regulate the firing of periaqueductal grey neurons via a GABA-
mediated action, and interfere with the chronic sensitization processes in the rostral 












atenolol is likely to be mediated by its β2 adrenoreceptor blocking activity. Although 
classified as β1 selective, its β1/β2 adrenoreceptor selectivity is relatively modest at 
4.7(40).  
This study suggests that β1-adrenoreceptor selective drugs may also have an 
analgesic effect. This is consistent with the findings of a previous cross-sectional study 
(16), and that of another study using data from people undergoing total knee 
arthroplasty (41). In the latter study, β-blocker prescription was associated with lower 
opioid use at day 30 (aOR(95%CI) 0.89(0.80-0.99)) (41). Ninety percent of participants 
in this study were prescribed β1-adrenoreceptor selective drugs (41). However, the 
findings of these studies are not consistent with those of a study using data from the 
Osteoarthritis Initiative (17). That study reported comparable pain score, proportion 
reporting widespread pain, and opioid consumption in people with knee OA prescribed 
β-blockers and other anti-hypertensive medications (17). However, that was a 
hospital-based study with a different comparator i.e. “prescription of another anti-
hypertensive drug”, had a relatively modest sample size (n=1168), and only 15% 
participants were prescribed β-blockers resulting in potential type-2 error (17).  
Strengths of this study include a large sample size, balanced PS matched exposed 
and un-exposed groups, and adjustment for covariates that reflect health seeking 
behaviour, or are risk factors for OA. GPs are the first physician option for people with 
chronic conditions in the UK, and it is extremely unlikely that someone with OA will be 
seen in a hospital service, including in private settings, for the first time, without ever 
consulting their GP. Only GPs refer patients to NHS hospitals for long-term conditions. 
Participants with less than two year registration in the general practice surgery before 
the index date were excluded to reduce the chance of prevalent cases being classified 












and contra-indications to β-blockers to minimise confounding by indication that may 
not be addressed by PS matching.  
However, there are several caveats. Firstly, we could not undertake multiple 
imputation to account for missing smoking status and BMI data because these were 
missing in 50.5% and 60.3% participants respectively, and multiple imputation is not 
recommended with such degree of missingness (22, 23). In addition, smoking and BMI 
are not missing at random in consultation-based databases, therefore multiple 
imputation should not be used (24, 25). Secondly, CPRD participants with missing 
data are likely to be healthier. After PS matching there was a comparable proportion 
of people in exposed and unexposed groups with missing data on BMI and smoking 
minimising any potential for confounding. Thirdly, we used GP diagnosis of OA to 
define our primary outcome. Although this has been validated previously (19, 20), its’ 
PPV for OA diagnosis is c. 80% and some participants may not be diagnosed, limiting 
the validity of our findings. We used primary care consultations to define the outcomes. 
This is later than the onset of symptoms as most patients defer seeing their GP for 
chronic musculoskeletal pain. However, there is no reason to suspect that this delay 
will differ between the groups. Similarly, access to GP surgery and ability to pay for 
repeat prescription may also affect the results. This is likely to play a small role as 
healthcare is free at the point of delivery in the NHS and socio-economically 
disadvantaged patients are eligible for free NHS prescriptions. Furthermore, we did 
not examine the association between β-blocker prescription and total joint 
replacement in this study as the mean follow-up was short. Finally, we only 
dichotomised the exposure as two or more than two prescriptions within 60 days. 
Further dose response analysis, examining the association between cumulative dose 












In summary, both non-selective and selective β-blockers may reduce the cumulative 
risk of incident OA. Atenolol might be a consideration for people with OA and 
cardiovascular co-morbidities, while propranolol may be suitable in people with OA 
and anxiety. However, a RCT is necessary to further evaluate these possibilities 
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Figure 1: Cumulative hazard of (A) knee osteoarthritis and (B) knee pain consultation 
in β-blocker exposed and unexposed participants. Data restricted to the last 














Figure 2: Cumulative hazard of (A) knee osteoarthritis and (B) knee pain consultation 
in atenolol and propranolol exposed and unexposed participants. Data restricted to the 














 Table 1: The association between β-blocker prescription and primary-care consultation for incident osteoarthritis and joint 
pain: follow-up period restricted to end of β-blocker prescription (n=223,436) 
Outcomes Exposed  Events (n) Person-time 
(years)  
Event rate (95% CI)/  
1,000 person-years 
PS matched    
HR (95% CI) 
PS matched and 
adjusted 
HR (95% CI)1 
Knee osteoarthritis  No 986 262,003 3.76 (3.54 – 4.01) 1.00 1.00 
Yes 1,101 307,231 3.58 (3.38 – 3.80) 0.90 (0.83 – 0.99) 0.90 (0.83 – 0.98) 
Hip osteoarthritis  No 451 263,753 1.71 (1.56– 1.87) 1.00 1.00 
Yes 530 310,045 1.71 (1.57 – 1.86) 0.94 (0.83 – 1.06) 0.94 (0.83 – 1.07) 
Knee pain No 3,074 255,003 12.06 (11.64 – 12.49) 1.00 1.00 
Yes 3,560 297,027 11.99 (11.60 – 12.37) 0.91 (0.87 – 0.96) 0.88 (0.83 – 0.92) 
Hip pain No 1,767 259,515 6.81 (6.50 – 7.13) 1.00 1.00 
Yes 1,981 304,454 6.51 (6.23 - 6.80) 0.87 (0.82 – 0.93) 0.85 (0.79 – 0.90) 
1adjusted for age, number of GP consultations, hospital out-patient referrals, hospital admissions in the 12-month period preceding cohort entry, total number 



















Table 2: The association between β-blocker prescription and primary-care consultation for incident osteoarthritis and joint pain:  
follow-up period not restricted to end of β-blocker prescription (n=223,436). 
 
Outcomes Exposed  Events  Person-time (years) Event rate (95% CI)/ 
1,000 person-years 
PS matched   
HR (95% CI) 
PS matched and 
adjusted  
HR (95% CI)1 
Knee osteoarthritis  No  4,809 1,118,936 4.30 (4.12-4.42) 1.00 1.00 
Yes  5,330 1,261,516 4.23 (4.11-4.34) 0.96 (0.92-1.00) 0.97 (0.93-1.01) 
Hip osteoarthritis  No  2,253 1,137,529 1.98 (1.90-2.06) 1.00 1.00 
Yes  2,512 1,282,641 1.96 (1.88-2.04) 0.96 (0.91-1.02) 0.98 (0.93-1.04) 
Knee pain    No 15,921 1,049,982 15.16 (14.93-15.40) 1.00 1.00 
Yes  19,473 1,168,291 16.67 (16.44-16.90) 1.07 (1.05-1.09) 1.03 (1.01-1.05) 
Hip pain     No  9,392 1,095,747 8.57 (8.40-8.75) 1.00 1.00 
Yes  11,532 1,225,992 9.41 (9.24-9.58) 1.06 (1.03-1.09) 1.04 (1.02-1.07) 
 
1 adjusted for age, number of GP consultations, hospital out-patient referrals, hospital admissions in the 12 month period preceding cohort entry, total number of GP 













Table 3: The association between β-blocker prescription and incident osteoarthritis and pain: stratified according to drug class 
 Knee osteoarthritis  
 
Knee pain  
 




















Unexposed1 986 262,003 3.76  
(3.54-4.01) 











































 Hip osteoarthritis   Hip pain  
Unexposed1 451 263,753 1.71 
(1.56-1.88) 











































 1Comparison group is unexposed to β-blockers; ≠β-blocker properties 2Propensity score matched and adjusted for age, number of GP consultations, hospital out-patient referrals, hospital 
admissions in the 12 month period preceding cohort entry, total number of GP consultations for knee or hip injury prior to cohort entry and non-osteoporotic fractures; ISE: Intrinsic sympathomimetic 
effect; MSE: membrane stabilising effect. Drugs from the rest of β-blocker class combinations are not used in clinical practice. Lipophilic non-selective β-blockers, lipophilic non-selective β-blockers 
with ISE and MSE, low-lipophilic non-selective β-blockers with ISE and MSE, low lipophilic β1-selecive blockers with ISE and MSE were excluded as the number of outcome events were fewer than 















Table 4: The association between commonly prescribed β-adrenoreceptor blocking drugs and incident osteoarthritis and pain  
 Knee osteoarthritis  
 
Knee pain  
 













PS matched and 
adjusted HR2 
95% CI 
Unexposed1 986 262,003 3.76  
(3.54-4.01) 
1 3,074 255,003 12.06 
 (11.64-12.49) 
1 








































 Hip osteoarthritis  Hip pain  
Unexposed1 451 263,753 1.71 
(1.56-1.88) 























































1Comparison group is unexposed to β-blockers; 2Propensity score matched and adjusted for age, number of GP consultations, hospital out-patient referrals, hospital admissions in the 12 month 
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